Another Big Pharma Embraces AI As Exscientia Bags GSK
GSK's deal with Exscientia will see the Scottish artificial intelligence pioneer discover new small molecules against targets selected by the big pharma. Exscientia is already working with Sanofi, Evotec, Sumitomo Dainippon Pharma and Sunovion across a range of disease areas, and is in talks with others.
You may also be interested in...
Evotec has deepened its relationship with artificial intelligence company Exscientia by investing €15m in the UK-based company; the CRO wants to build on the pair's existing collaboration in immuno-oncology and use its stake to diversify the AI firm's portfolio.
Servier and Transgene will collaborate to apply viral vector technology to the development of CAR-T therapeutics, while Chinese vaccine maker Sinovac is taken private by an investment consortium.
Sanofi hopes to use Exscientia's artificial intelligence (AI) platform to develop bispecific-small-molecule drugs for diabetes and associated metabolic conditions.